| Name | Title | Contact Details |
|---|
As a world-class academic and health care system, Duke Health strives to transform medicine and health locally and globally through innovative scientific research, rapid translation of breakthrough discoveries, educating future clinical and scientific leaders, advocating and practicing evidence-based medicine to improve community health, and leading efforts to eliminate health inequalities.
AHRI is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Indiana Health Information Exchange operates the nation’s largest health information exchange, providing a secure, robust and interoperable health information technology network that connects over 100 hospitals, long-term care facilities, rehabilitation centers, community health clinics and other healthcare providers. IHIE provides the nation’s largest implementation of clinical results delivery in the country (DOCS4DOCS® Service). The organization supports the Indiana Network for Patient Care, a clinical data repository accessed via IHIE’s CareWeb application. IHIE also provides Public Health, Transitions of Care and Population Health Management Services.
Meridian Health Services provides a safe, medically-supervised environment that respects your privacy and supports your physical and emotional health.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.